Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of DAA Treatment on Seminal Parameters in HCV
NCT05616598Phase 3Completed
- Sponsor
- Benha University
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir, daclatasvir, simeprevir, ribavirin in hepatitis C (HCV), sponsored by Benha University. Started Mar 2022; status: completed.
02
Drugs
sofosbuvirdaclatasvirsimeprevirribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05616598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616598.